A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT05650632 · RECRUITING

Trial details

NCT number: NCT05650632
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2023-03-21
Primary completion: 2029-08-01
Enrollment: 210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.